The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding ...

VeonGen aligns with FDA on phase 3 design for VG801, a dual-AAV Stargardt gene therapy, after uncontrolled phase 1/2 BCVA ...

From the first BLA acceptance for a gene-agnostic optogenetic therapy to the first pivotal gene therapy trial in geographic ...

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted ...

Isa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery ...

Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...

Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual ...

AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements ...

In more than 90,000 people across TWO independent cohorts, those with atrial fibrillaion (AF) had a thinner macular ganglion ...